ProQR Therapeutics N.V.

NasdaqCM:PRQR Stock Report

Market Cap: US$372.6m

ProQR Therapeutics Past Earnings Performance

Past criteria checks 0/6

ProQR Therapeutics has been growing earnings at an average annual rate of 9.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 51.2% per year.

Key information

9.9%

Earnings growth rate

23.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate51.2%
Return on equity-95.8%
Net Margin-130.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

Oct 23
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Jul 15
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

May 29
Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Apr 03
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Nov 28
Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Jul 30
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Mar 17
Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

ProQR says EU regulator seeks additional trial for lead candidate

Aug 11

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Nov 10
Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Investment Case On ProQR Therapeutics Gets More Enticing

Oct 01

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Aug 04
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

Jun 20

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

May 13
It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

ProQR Therapeutics offers a de-risked opportunity: Stifel

May 03

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Mar 08
If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Feb 01
Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder

Jan 07

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Dec 28
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Dec 01
A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Revenue & Expenses Breakdown

How ProQR Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:PRQR Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2418-241433
30 Jun 2416-221530
31 Mar 2411-271628
31 Dec 237-281625
30 Sep 235-361428
30 Jun 234-541738
31 Mar 234-591844
31 Dec 224-641951
30 Sep 224-692153
30 Jun 224-612048
31 Mar 223-631947
31 Dec 212-611742
30 Sep 212-571638
30 Jun 212-551435
31 Mar 211-431334
31 Dec 201-471438
30 Sep 201-521444
30 Jun 201-511446
31 Mar 202-581447
31 Dec 192-561346
30 Sep 193-511442
30 Jun 195-451337
31 Mar 196-401334
31 Dec 186-371330
30 Sep 184-351128
30 Jun 182-401129
31 Mar 181-441131
31 Dec 171-441131
30 Sep 171-411031
30 Jun 171-41932
31 Mar 171-39933
31 Dec 162-39932
30 Sep 163-36930
30 Jun 163-33928
31 Mar 163-31825
31 Dec 153-21723
30 Sep 153-17720
30 Jun 151-14817
31 Mar 151-10814
31 Dec 140-12710
30 Sep 140-1258
30 Jun 140-936
31 Mar 140-514
31 Dec 130-313

Quality Earnings: PRQR is currently unprofitable.

Growing Profit Margin: PRQR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PRQR is unprofitable, but has reduced losses over the past 5 years at a rate of 9.9% per year.

Accelerating Growth: Unable to compare PRQR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRQR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: PRQR has a negative Return on Equity (-95.83%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies